Overview
Go Beyond the Gut: Insights and Commentary for Appropriate Vaccination of the Immunosuppressed IBD Patient
Appropriate Vaccination of the Immunosuppressed IBD Patient Online Clinical Commentary
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this clinical commentary, a panel of three faculty experts will discuss the importance of immunity assessments/titers and appropriate vaccinations for Inflammatory bowel disease (IBD) patients on immunosuppressive therapies, ACG clinical practice guidelines, strategies for improving vaccination rates, and the administrative, financial, and communication related challenges surrounding vaccines and immunity assessments for IBD patients. Because the patient plays such a critical role in shared decision-making, this activity will also include an actual patient sharing her perspectives, experiences, and treatment goals.
This activity is intended for gastroenterologists, OB/GYN’s, primary care physicians, nurse practitioners, physician assistants and other members of the IBD multidisciplinary care team.
There is an increasing call for a treat-to-target approach in IBD. Given the higher risk of infection for IBD patients on immunosuppressive therapies, and the inherent complexity and low adaptation levels of the 2017 ACG preventive care/vaccine guidelines for IBD patients, additional targeted education of the gastroenterology profession is warranted.
Upon completion of this activity, participants will be able to:
• Outline clinical importance of immunity assessments/titers and appropriate vaccinations for IBD patients on immunosuppressive therapies.
• Interpret vaccine- and immunity-related protocols in the 2017 ACG clinical practice guideline on preventive care for IBD patients.
• Discuss strategies for improving vaccination rates and immunity-related assessments of IBD patients in the gastroenterology care setting.
• List administrative, financial, and communication-related challenges surrounding vaccines and immunity assessments for IBD patients.
• Outline clinical importance of immunity assessments/titers and appropriate vaccinations for IBD patients on immunosuppressive therapies.
• Interpret vaccine- and immunity-related protocols in the 2017 ACG clinical practice guideline on preventive care for IBD patients.
• Discuss strategies for improving vaccination rates and immunity-related assessments of IBD patients in the gastroenterology care setting.
• List administrative, financial, and communication-related challenges surrounding vaccines and immunity assessments for IBD patients.
Supported by an educational grant from Merck & Co.
Ryan Ungaro, MD
Assistant Professor
The Susan and Leonard Feinstein IBD Clinical Center
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY
Assistant Professor
The Susan and Leonard Feinstein IBD Clinical Center
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY
Sharmeel Wasan, MD
Fellowship Director
Section of Gastroenterology
Boston Medical Center
Assistant Professor of Medicine
Boston University School of Medicine
Boston, MA
Jason Worcester, MD
Assistant Professor of Medicine
Boston University School of Medicine
Medical Director, Adult Primary Care
Boston Medical Center
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Ryan Ungaro, MD (Faculty)
Advisory Board: Janssen
Consultant: Takeda
Research Grant: AbbVie
Sharmeel Wasan, MD (Faculty)
Nothing to disclose
Jason Worcester, MD (Faculty)
Nothing to disclose
Heather (Patient)
Nothing to Disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider approved by the California Board of Registered Nursing, Provider Number 14803 for 1 contact hour.